Sergey Semochkin
Overview
Explore the profile of Sergey Semochkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Botton S, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei A, et al.
Blood
. 2022 Jun;
141(2):156-167.
PMID: 35714312
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute...
2.
Richardson P, Oriol A, Beksac M, Liberati A, Galli M, Schjesvold F, et al.
Lancet Oncol
. 2019 May;
20(6):781-794.
PMID: 31097405
Background: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and...
3.
Chanan-Khan A, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, et al.
Lancet Haematol
. 2017 Sep;
4(11):e534-e543.
PMID: 28958469
Background: The efficacy and safety of lenalidomide as maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic leukaemia is unknown. Although kinase inhibitors can improve outcomes for some...